The present invention provides an antibody to human IL-3R chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R chain but does not bind to C domain of the human IL-3R chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R antibody as an active ingredient.

The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin 2 chain, expression vectors and host cells thereof.

The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR chain, TCR chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a -defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5 cap or a 3 extension.